Biopharma companies are showing signs of recovery as they work through another quarter of deal and funding challenges. On the medtech front, activity remains muted—but there are pockets of positive data.
Biopharma venture activity increased in the second quarter of 2023, even as R&D partnerships declined to their lowest quarterly volume in more than five years.
J.P. Morgan’s biopharma therapeutics and medtech licensing reports explore the movement in each sector, offering insight on industry trends that will shape the back half of 2023. The reports, powered by DealForma, highlight:
Download the full reports to better understand these dealmaking trends.
Mar 01, 2024
Here’s where we stand as investors clash over inflation, stock market highs and Washington dysfunction.
Feb 23, 2024
Nvidia made new milestones this week, but the rally wasn't just big tech. Today, we unpack the moves across the globe and where we see opportunity.
Feb 14, 2024
The January CPI report offered an unwelcome surprise to the upside and sent markets tumbling.
Feb 14, 2024
Across several global innovation hubs, leaders of venture-backed, high-growth companies are hopeful about their prospects.
Feb 09, 2024
Megacap stocks just delivered another round of stellar results. What did we learn and can the momentum continue?
Feb 08, 2024
Five Easy Pieces: on Magnificent 7 stocks, open source large language models, the No Labels movement, the Armageddonists and bottom-fishing in Chinese equities.
Feb 05, 2024
The U.S. economy added a higher-than-expected 353,000 jobs in the first month of the year. Discover the details of the jobs report and the implications for Fed policy in 2024.
Feb 02, 2024
The Fed. Big rally jitters. Elections. Markets may have seen this movie before.
You're now leaving J.P. Morgan
J.P. Morgan’s website and/or mobile terms, privacy and security policies don’t apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan isn’t responsible for (and doesn’t provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan name.